Equities research analysts forecast that Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) will announce sales of $50,000.00 for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Aurinia Pharmaceuticals’ earnings, with the highest sales estimate coming in at $100,000.00 and the lowest estimate coming in at $30,000.00. Aurinia Pharmaceuticals reported sales of $30,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 66.7%. The business is scheduled to issue its next quarterly earnings results on Thursday, March 21st.

On average, analysts expect that Aurinia Pharmaceuticals will report full-year sales of $360,000.00 for the current fiscal year, with estimates ranging from $120,000.00 to $500,000.00. For the next financial year, analysts anticipate that the firm will post sales of $180,000.00, with estimates ranging from $120,000.00 to $300,000.00. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Aurinia Pharmaceuticals.

AUPH has been the subject of several research reports. BidaskClub downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 25th. Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research note on Wednesday, January 9th. Finally, ValuEngine upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 16th. One analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $12.94.

Aurinia Pharmaceuticals stock traded up $0.04 during trading on Wednesday, hitting $6.61. The company had a trading volume of 143,682 shares, compared to its average volume of 1,176,325. The company has a market capitalization of $565.16 million, a PE ratio of -7.18 and a beta of 1.38. Aurinia Pharmaceuticals has a 1-year low of $5.01 and a 1-year high of $7.85.

Several large investors have recently bought and sold shares of the business. D. E. Shaw & Co. Inc. grew its stake in shares of Aurinia Pharmaceuticals by 47.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 388,811 shares of the biotechnology company’s stock worth $2,652,000 after acquiring an additional 124,940 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Aurinia Pharmaceuticals by 8,600.6% in the fourth quarter. Bank of America Corp DE now owns 30,713 shares of the biotechnology company’s stock worth $210,000 after acquiring an additional 30,360 shares in the last quarter. Polar Capital LLP grew its stake in shares of Aurinia Pharmaceuticals by 17.8% in the fourth quarter. Polar Capital LLP now owns 3,312,723 shares of the biotechnology company’s stock worth $22,593,000 after acquiring an additional 501,207 shares in the last quarter. Creative Planning grew its stake in shares of Aurinia Pharmaceuticals by 10.2% in the fourth quarter. Creative Planning now owns 167,657 shares of the biotechnology company’s stock worth $1,143,000 after acquiring an additional 15,457 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Aurinia Pharmaceuticals by 168.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,104 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 3,828 shares in the last quarter. Institutional investors and hedge funds own 25.08% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Article: Call Option

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.